- Home
- CRCT vs ARVN Comparison
CRCT vs ARVN Comparison
Compare CRCT & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRCT
- ARVN
- Stock Information
- Founded
- CRCT 1969
- ARVN 2015
- Country
- CRCT United States
- ARVN United States
- Employees
- CRCT N/A
- ARVN N/A
- Industry
- CRCT Wholesale Distributors
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- CRCT Industrials
- ARVN Health Care
- Exchange
- CRCT Nasdaq
- ARVN Nasdaq
- Market Cap
- CRCT N/A
- ARVN 1.2B
- IPO Year
- CRCT 2021
- ARVN 2018
- Fundamental
- Price
- CRCT $5.16
- ARVN $7.59
- Analyst Decision
- CRCT Sell
- ARVN Buy
- Analyst Count
- CRCT 2
- ARVN 13
- Target Price
- CRCT $4.78
- ARVN $34.42
- AVG Volume (30 Days)
- CRCT 405.3K
- ARVN 3.3M
- Earning Date
- CRCT 03-04-2025
- ARVN 05-06-2025
- Dividend Yield
- CRCT 11.69%
- ARVN N/A
- EPS Growth
- CRCT 20.83
- ARVN N/A
- EPS
- CRCT 0.29
- ARVN N/A
- Revenue
- CRCT $712,538,000.00
- ARVN $263,399,999.00
- Revenue This Year
- CRCT $2.83
- ARVN N/A
- Revenue Next Year
- CRCT $2.37
- ARVN $7.99
- P/E Ratio
- CRCT $18.00
- ARVN N/A
- Revenue Growth
- CRCT N/A
- ARVN 235.54
- 52 Week Low
- CRCT $4.66
- ARVN $7.53
- 52 Week High
- CRCT $8.40
- ARVN $41.34
- Technical
- Relative Strength Index (RSI)
- CRCT 40.17
- ARVN 25.11
- Support Level
- CRCT $5.10
- ARVN $8.51
- Resistance Level
- CRCT $5.26
- ARVN $9.17
- Average True Range (ATR)
- CRCT 0.18
- ARVN 0.72
- MACD
- CRCT -0.02
- ARVN -0.07
- Stochastic Oscillator
- CRCT 14.29
- ARVN 1.85
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.